Reader TTS

Vertex Pharmaceuticals will promote Reshma Kewalramani, its chief medical officer, to president and CEO on April 1, the company announced Thursday morning. She will succeed Jeffrey Leiden,

who said he would step down as president and CEO after seven years in those roles. Leiden, who has also served as chairman, will become executive chairman, a position he will hold through

the first quarter of 2023. Kewalramani, 46, will become the first woman to run a large biotechnology firm, a watershed moment for an industry that in 2018 had more men named “Michael” than

women speak at its largest conference. Expectations are high. Under Leiden’s tenure, Vertex’s share price rose 360% and its sales doubled to $3 billion annually as the company sold

$300,000-a-year medicines that have a dramatic effect on some patients with cystic fibrosis, or CF, a genetic disease that robs patients of their lung function. STAT+ Exclusive Story Already

have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS DAILY COVERAGE AND ANALYSIS OF THE BIOTECH SECTOR — BY SUBSCRIBING TO STAT+. Already have

an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe